Christian Gentner, Ph.D., Joins Zageno as Vice President European Sales
Highly consultative method of sales ensures each customer’s unique needs are heard, understood, and served to create a tailored solution that simplifies and streamlines administrative laboratory purchasing tasks across the enterprise and lets them focus on what really matters: their scientific and business milestones
CAMBRIDGE, Mass. USA and BERLIN, Germany, Sept. 12, 2018 (GLOBE NEWSWIRE) --
, the largest and fastest-growing online marketplace for the research scientist, has just named Christian Gentner, Ph.D., vice president, European sales. A seasoned sales executive, with nearly two decades of sales leadership experience in pharmaceutical and medical devices at companies such as Sanofi-Aventis, Essex Pharma, Bristol-Myers Squibb, Aspen Germany GmbH, and most recently, Urgo Medical — Gentner joined Zageno to evolve the company’s sales and commercial processes to support an expanded, multi-channel approach. This highly consultative method of sales ensures each customer’s unique needs are heard, understood, and served.
“We’ve had tremendous momentum, and our young sales team has done extraordinarily well, enabling us to far exceed our growth goals to date. We’re very excited to have Christian join us to take us to the next level of commercialization,” said Zageno Chief Executive Officer David Pumberger, Ph.D. “He has the skills, track record, and experience to transition our sales approach so that we become a more consultative, specific solutions provider for our various types of customers — from academic and government research institutions, biotechs startups and pharmaceuticals companies large and small —to CRO labs. His ability to lead, train, and mentor a team, and work in a cross-functional way was a key factor in our hiring decision.”
Zageno has three primary focus groups within in each customer site: the research scientists, the lab manager, and purchasing administrator. Its online marketplace and enterprise offering serves all three functions — simplifying and streamlining product selection through approvals to order receipt.
AtBMS, Gentner was a key member of a multi-function pre-launch team that provided the critical voice-of-the-customer perspective, allowing for the team to have customer-based, 360-degree insight for the HCV pipeline of products. As a result, he outperformed the sales goal post-launch.
Zageno Chief Revenue Officer Florian Wegener, M.D., M.B.A., Ph.D., commented, “At Zageno, we work hand-in-hand with our customers in the U.S., Germany, and the U.K. to provide a tailored solution that simplifies and streamlines administrative laboratory purchasing tasks across the enterprise to let them focus resources on what really matters: their scientific and business milestones. With Christian’s extensive connections, knowledge about, and stellar reputation within our target customer groups — we will be very well positioned to deliver excellent customer service and meet their specific needs.”
Genter’s approach is metrics-based, with a time horizon greater than the typical one-year sales outlook. His sales plans are linked strongly to both leadership’s key performance indicators (KPI) and the company’s strategic plan. This longer-range vision allows him to analyze the marketplace ecosystem and take a proactive approach in identifying opportunities and mitigating risks. Hegives his team members ownership of their territories and accounts, providing regular mentoring and check-in sessions to help them go beyond the science to become even more effective listeners and communicators to ensure that customers’ known and latent needs are met successfully. It’s how he’s built a strong track record of consistently delighting customers and exceeding sales goals.
About Zageno Inc. (www.zageno.com; twitter: @ZAGENOteam)
Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions’ procurement offices with leading life-science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising about five million products. What do we do? 1) We make purchasing transactions more efficient for both buyers and sellers. 2) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 3) We provide a valuable, expanded sales channel for our vendor partners. The growing Zageno team of 60 in Cambridge, USA, and Berlin, Germany, includes accessible experts in science, e-commerce, systems integration, and customer support. Our people work directly with customers to enable smarter, faster processes — allowing more time and resources for value-added science and better research results.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08 | Pressemelding
– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month
UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07 | Pressemelding
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol
Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44 | Pressemelding
SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo
Anomali Announces Major Expansion of Threat Platform Partner Ecosystem20.9.2018 16:00 | Pressemelding
New Developer SDKs enable partners to integrate solutions with Anomali Threat Platform NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the expansion of the partner ecosystem with the launch of a suite of partner developer resources. The new tools enable easier and faster integration with the Anomali Threat Platform and APP Store, allowing clients immediate access to partner content, integrations and analytics. The partner program expansion includes the launch of a suite of software development kits (SDKs). The SDKs address three critical integration areas: Threat Intelligence Feeds SDK: integrate proprietary threat intelligence feeds and make these accessible via the APP Store Integration SDK: integrate threat intelligence from the Anomali Threat Platform into third party products and solutions Enrichment SDK: integrate 3rd party threat analysis and data enrichments into the Anomali Threat Platform “Organizations need a com
Anomali Launches Comprehensive Threat Platform to Detect and Respond to Cyber Attacks20.9.2018 16:00 | Pressemelding
New Anomali Threat Platform delivers complete threat detection, analysis and response NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the launch of the Anomali Threat Platform, a comprehensive threat detection and response suite. The Anomali Threat Platform represents the culmination of five years of ongoing innovation to provide organizations a unified solution to identify cyberthreats, understand the adversary, and automate response. The Anomali Threat Platform is comprised of five core capabilities, each addressing a specific need for threat mitigation, and all working together to deliver a complete security solution. Intelligence: collection, optimization and enrichment of threat intelligence Investigation: understand cyber threats with comprehensive analyst workbench Detection: proactive detection of active, serious threats targeting client networks Automation: eliminate manual processes and streamline investigation an
Taconic Biosciences Becomes the First Animal Model Provider on Federal General Services Administration20.9.2018 15:40 | Pressemelding
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory products and equipment to federal, state, and local governments. Most notably, GSS has direct procurement relationships with the federal General Services Administration (GSA). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and also the only provider with a channel to the GSA. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable res
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom